AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27022958 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (reviewing symptom management and return to activity with parents at 1 week and 1 month postinjury)
Number of subjects: 66
Study 27022958 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no formalized follow‐up)
Number of subjects: 66
Study 25023947 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliCap® device with diltiazem (60 mg)
Number of subjects: 14
Study 25023947 — intervention group
Group type: COMPARATOR
Intervention: Mylan formulation (SR diffusion coated beads)
Number of subjects: 14
Study 22615342 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/d)
Number of subjects: 30
Study 22615342 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet with low cholesterol intake (<300 mg/d)
Number of subjects: 30
Study 20231684 — intervention group
Group type: EXPERIMENTAL
Intervention: HSPB1 promoter -1271C allele
Number of subjects: 1152
Study 20231684 — intervention group
Group type: COMPARATOR
Intervention: HSPB1 promoter -1271G allele
Number of subjects: 1152
Study 18227981 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 0.125% bupivacaine plus 50 microg fentanyl
Number of subjects: 30
Study 18227981 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia with 1.5 microg/ml/kg/h fentanyl followed by 1.0 microg/ml/kg/h fentanyl
Number of subjects: 30
Study 15959668 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 16
Study 15959668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12623333 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-flow duplex scanning
Number of subjects: 32
Study 10551568 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/kg perflubron emulsion with colloid (total = 450 ml) at FIO2 = 1.0
Number of subjects: 147
Study 10551568 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g/kg perflubron emulsion with colloid (total = 450 ml) at FIO2 = 1.0
Number of subjects: 147
Study 10551568 — intervention group
Group type: COMPARATOR
Intervention: Autologous blood harvested during acute normovolemic hemodilution at FIO2 = 0.40
Number of subjects: 147
Study 10551568 — intervention group
Group type: COMPARATOR
Intervention: Colloid at FIO2 = 1.0
Number of subjects: 147
Study 8903371 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of interferon alfa‐2b thrice weekly for 12 weeks
Number of subjects: 248
Study 8903371 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU of interferon alfa‐2b thrice weekly for 12 weeks
Number of subjects: 248
Study 8903371 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 MU of interferon alfa‐2b thrice weekly for 12 weeks
Number of subjects: 248
Study 8903371 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued therapy at 3 MU for an additional 12 weeks for nonresponders
Number of subjects: 248
Study 8903371 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated dose from 3 or 5 MU to 10 MU for nonresponders
Number of subjects: 248
Study 8903371 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of interferon (above 3 MU)
Number of subjects: 248
Study 1437036 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 86
Study 1437036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin rinse
Number of subjects: 86
Study 1437036 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution rinse
Number of subjects: 86
Study 3849034 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-coping technique
Number of subjects: 168
Study 3849034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-coping technique
Number of subjects: 168
Study 3849034 — intervention group
Group type: EXPERIMENTAL
Intervention: Concrete sensory information
Number of subjects: 168
Study 3849034 — intervention group
Group type: COMPARATOR
Intervention: Control information about the posthospital experience
Number of subjects: 168
Study 30413902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-PNI group
Number of subjects: 228
Study 30413902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-PNI group
Number of subjects: 228
Study 30413902 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 228
Study 30204493 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training in hypoxia (IHT; FIO2 = 17.2%; n=13)
Number of subjects: 86
Study 30204493 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-sprint training in hypoxia (RSH; FIO2 = 17.2%; n=15)
Number of subjects: 86
Study 30204493 — intervention group
Group type: COMPARATOR
Intervention: Interval training in normoxia (INT; n=15)
Number of subjects: 86
Study 30204493 — intervention group
Group type: COMPARATOR
Intervention: Repeated-sprint training in normoxia (RSN; n=18)
Number of subjects: 86
Study 30204493 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training in hypoxia (IHT; FIO2 = 17.2%) and Repeated-sprint training in hypoxia (RSH; FIO2 = 17.2%)
Number of subjects: 86
Study 30204493 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training in hypoxia (IHT) and Repeated-sprint training in hypoxia (RSH)
Number of subjects: 86
Study 25236992 — intervention group
Group type: EXPERIMENTAL
Intervention: Roland Morris Questionnaire (RMQ)
Number of subjects: 701
Study 25236992 — intervention group
Group type: EXPERIMENTAL
Intervention: RMQ to EQ-5D mapping model
Number of subjects: 701
Study 25236992 — intervention group
Group type: EXPERIMENTAL
Intervention: RMQ to SF-6D mapping model
Number of subjects: 701
Study 21850408 — intervention group
Group type: EXPERIMENTAL
Intervention: Antirefluxive DJ stent
Number of subjects: 29
Study 21850408 — intervention group
Group type: COMPARATOR
Intervention: Conventional DJ stent
Number of subjects: 29
Study 21199471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)
Number of subjects: 63
Study 18087084 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g single oral dose azithromycin
Number of subjects: 75
Study 18087084 — intervention group
Group type: COMPARATOR
Intervention: 250 mg parenteral ceftriaxone
Number of subjects: 75
Study 16253590 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 1314
Study 16253590 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (Control)
Number of subjects: 1314
Study 12010164 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant prostheses (IG, n = 26)
Number of subjects: 83
Study 12010164 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dentures (CDG2, n = 35)
Number of subjects: 83
Study 12010164 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures (CDG1, n = 22)
Number of subjects: 83
Study 10096530 — intervention group
Group type: EXPERIMENTAL
Intervention: enlimomab
Number of subjects: 262
Study 10096530 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 262
Study 7655889 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cued movements in Parkinson's disease
Number of subjects: 0
Study 7655889 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally cued movements in Parkinson's disease
Number of subjects: 0
Study 7655889 — intervention group
Group type: COMPARATOR
Intervention: Non-cued movements in controls
Number of subjects: 0
Study 7655889 — intervention group
Group type: COMPARATOR
Intervention: Externally cued, predictable movements in controls
Number of subjects: 0
Study 7655889 — intervention group
Group type: COMPARATOR
Intervention: Externally cued, unpredictable movements in controls
Number of subjects: 0
Study 2681593 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study 2681593 — intervention group
Group type: EXPERIMENTAL
Intervention: Other drugs modifying myogenic tone
Number of subjects: 0
Study 1093507 — intervention group
Group type: EXPERIMENTAL
Intervention: Marihuana
Number of subjects: 12
Study 1093507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29389691 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC-2h (Ischemic Preconditioning 2 hours before swimming)
Number of subjects: 20
Study 29389691 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC-24h (Ischemic Preconditioning 24 hours before swimming)
Number of subjects: 20
Study 29389691 — intervention group
Group type: COMPARATOR
Intervention: Con (Control with sham intervention 2 hours before swimming)
Number of subjects: 20
Study 29950106 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use self-efficacy
Number of subjects: 0
Study 29950106 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use norms
Number of subjects: 0
Study 29950106 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes toward condom use
Number of subjects: 0
Study 29950106 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use intentions
Number of subjects: 0
Study 29950106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation analysis of condom use intentions
Number of subjects: 0
Study 28333611 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 22
Study 28333611 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 22
Study 25776217 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (experimental)
Number of subjects: 120
Study 25776217 — intervention group
Group type: COMPARATOR
Intervention: Control condition (non-stress)
Number of subjects: 120
Study 23759361 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver educational programme performed by nurses to improve skills in meal support, nursing care, welfare care, or symptom management.
Number of subjects: 67
Study 23759361 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver educational programme (experimental group)
Number of subjects: 67
Study 23759361 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 67
Study 21800090 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional risk factor scoring
Number of subjects: 865
Study 21800090 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment for both risk factors and subclinical atherosclerosis
Number of subjects: 865
Study 21800090 — intervention group
Group type: COMPARATOR
Intervention: Survey-only group
Number of subjects: 865
Study 18321517 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen suppository
Number of subjects: 142
Study 18321517 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 142
Study 17060041 — intervention group
Group type: EXPERIMENTAL
Intervention: U-Clip for proximal anastomoses
Number of subjects: 118
Study 17060041 — intervention group
Group type: EXPERIMENTAL
Intervention: U-Clip for distal anastomoses
Number of subjects: 118
Study 17060041 — intervention group
Group type: EXPERIMENTAL
Intervention: U-Clip for distal anastomoses in interim angiography
Number of subjects: 118
Study 17060041 — intervention group
Group type: EXPERIMENTAL
Intervention: U-Clip for proximal anastomoses in interim angiography
Number of subjects: 118
Study 17060041 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hospital mortality
Number of subjects: 118
Study 12661806 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (100 microg/puff) alone
Number of subjects: 57
Study 12661806 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone diproprionate (50 microg/puff) with Salbutamol (100 microg/puff) by metered dose inhaler with or without spacer
Number of subjects: 57
Study 12661806 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone diproprionate (50 microg/puff) with Salbutamol (100 microg/puff) without spacer
Number of subjects: 57
Study 11132785 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 to 20 channels of stimulation for normal-hearing children and adults
Number of subjects: 0
Study 11132785 — intervention group
Group type: COMPARATOR
Intervention: Nucleus 22 cochlear implant
Number of subjects: 0
Study 9366582 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐568 20 mg
Number of subjects: 20
Study 9366582 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐568 80 mg
Number of subjects: 20
Study 9366582 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐568 160 mg
Number of subjects: 20
Study 8447215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.1 mg
Number of subjects: 80
Study 8447215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.3 mg
Number of subjects: 80
Study 8447215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.5 mg
Number of subjects: 80
Study 8447215 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 mg intrathecal morphine)
Number of subjects: 80
Study 2439780 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 48
Study 2439780 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg
Number of subjects: 48
Study 2439780 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg
Number of subjects: 48
Study 2439780 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with bisoprolol (dose adjustments up or down)
Number of subjects: 48
Study 2439780 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of bisoprolol
Number of subjects: 48
Study 2439780 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory safety tests
Number of subjects: 48
Study 29458923 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Ai Chi program
Number of subjects: 29
Study 29458923 — intervention group
Group type: COMPARATOR
Intervention: Dry land conventional Western physical therapy intervention
Number of subjects: 29
Study 27431654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Coping with Depression Course (ACDC)
Number of subjects: 0
Study 27431654 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24855350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol
Number of subjects: 3255
Study 24855350 — intervention group
Group type: COMPARATOR
Intervention: Vilanterol alone
Number of subjects: 3255
Study 23090339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) via nasal prongs
Number of subjects: 120
Study 23090339 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP) via nasal mask
Number of subjects: 120
Study 20132902 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over S1
Number of subjects: 27
Study 20132902 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 27
Study 17714557 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative proton pump inhibitor‐based triple therapy (rabeprazole 10 mg, clarithromycin 500 mg, amoxicillin 1,000 mg, twice daily for 7 days)
Number of subjects: 138
Study 17714557 — intervention group
Group type: COMPARATOR
Intervention: Postoperative proton pump inhibitor‐based triple therapy (rabeprazole 10 mg, clarithromycin 500 mg, amoxicillin 1,000 mg, twice daily for 7 days)
Number of subjects: 138
Study 17714557 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative proton pump inhibitor‐based triple therapy
Number of subjects: 138
Study 17714557 — intervention group
Group type: COMPARATOR
Intervention: Postoperative proton pump inhibitor‐based triple therapy
Number of subjects: 138
Study 17714557 — intervention group
Group type: COMPARATOR
Intervention: Postoperative proton pump inhibitor‐based triple therapy (Billroth I)
Number of subjects: 138
Study 17714557 — intervention group
Group type: COMPARATOR
Intervention: Postoperative proton pump inhibitor‐based triple therapy (Billroth II)
Number of subjects: 138
Study 16459898 — intervention group
Group type: EXPERIMENTAL
Intervention: Masking of T2 by a trailing item
Number of subjects: 0
Study 16459898 — intervention group
Group type: EXPERIMENTAL
Intervention: Silence following T2 instead of a trailing item
Number of subjects: 0
Study 16459898 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 as the last presented stimulus
Number of subjects: 0
Study 16459898 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed masking of T2
Number of subjects: 0
Study 12414333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 6
Study 10325830 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 0
Study 10325830 — intervention group
Group type: COMPARATOR
Intervention: 4% sevoflurane
Number of subjects: 0
Study 8568487 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil treatment
Number of subjects: 16
Study 8568487 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive, similar age)
Number of subjects: 16
Study 2009056 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (specific combinations not detailed)
Number of subjects: 1392
Study 2009056 — intervention group
Group type: COMPARATOR
Intervention: No systemic therapy (control group)
Number of subjects: 1392
Study 7272159 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily flurbiprofen
Number of subjects: 17
Study 7272159 — intervention group
Group type: COMPARATOR
Intervention: Four times daily flurbiprofen
Number of subjects: 17
Study 7272159 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily flurbiprofen without an evening dose
Number of subjects: 17
Study 7272159 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 17
Study 31376438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 42
Study 31376438 — intervention group
Group type: COMPARATOR
Intervention: Fed state
Number of subjects: 42
Study 31376438 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach food bias via SRCT
Number of subjects: 42
Study 31376438 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit attitudes to food cues via IAT
Number of subjects: 42
Study 30029461 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g/day polydextrose
Number of subjects: 128
Study 30029461 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g/day polydextrose
Number of subjects: 128
Study 30029461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 26779838 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based interactive breastfeeding monitoring system
Number of subjects: 141
Study 26779838 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital protocol (Control)
Number of subjects: 141
Study 24922494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.5 mg/kg) over 40 minutes
Number of subjects: 108
Study 21761341 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI) treatment
Number of subjects: 82
Study 19281871 — intervention group
Group type: EXPERIMENTAL
Intervention: staging acupuncture group
Number of subjects: 900
Study 19281871 — intervention group
Group type: EXPERIMENTAL
Intervention: staging acupuncture and moxibustion group
Number of subjects: 900
Study 19281871 — intervention group
Group type: EXPERIMENTAL
Intervention: staging electro-acupuncture group
Number of subjects: 900
Study 19281871 — intervention group
Group type: EXPERIMENTAL
Intervention: staging acupuncture along yangming musculature group
Number of subjects: 900
Study 19281871 — intervention group
Group type: COMPARATOR
Intervention: non-staging acupuncture control group
Number of subjects: 900
Study 17201538 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expression
Number of subjects: 0
Study 17201538 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of choice
Number of subjects: 0
Study 17201538 — intervention group
Group type: EXPERIMENTAL
Intervention: Value of expression
Number of subjects: 0
Study 15547086 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 200 mg/day
Number of subjects: 30
Study 15547086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11182190 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg tid plus conventional therapy (thrombolytic therapy, aspirin, beta-blocker, heparin, intravenous nitroglycerin)
Number of subjects: 64
Study 11182190 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (thrombolytic therapy, aspirin, beta-blocker, heparin, intravenous nitroglycerin)
Number of subjects: 64
Study 9337494 — intervention group
Group type: EXPERIMENTAL
Intervention: SST with parent‐mediated generalization (SST‐PG)
Number of subjects: 27
Study 9337494 — intervention group
Group type: EXPERIMENTAL
Intervention: Child‐only SST
Number of subjects: 27
Study 9337494 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 27
Study 7631093 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with L-Dopa and anticholinergics
Number of subjects: 3
Study 7631093 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamo-subthalamotomies plus medical treatment
Number of subjects: 3
Study 7631093 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous adrenal medullary transplantation plus medical treatment
Number of subjects: 3
Study 3283921 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g aztreonam as a single intramuscular injection
Number of subjects: 236
Study 3283921 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin plus probenecid
Number of subjects: 236
Study 29747091 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT)
Number of subjects: 112
Study 29747091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 27158085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen gel (2 g of 2.5% ketoprofen gel)
Number of subjects: 140
Study 27158085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 27158085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen gel
Number of subjects: 140
Study 24943961 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly azithromycin for 3 weeks
Number of subjects: 186
Study 24943961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 22619063 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir with peginterferon/ribavirin
Number of subjects: 681
Study 22619063 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 12 HCV RNA cutoff of ≥ 100 IU/mL stopping rule
Number of subjects: 681
Study 22619063 — intervention group
Group type: COMPARATOR
Intervention: Week 12 HCV RNA levels between 9.3 IU/mL and 25 IU/mL
Number of subjects: 681